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Abstract
Purpose: The study aimed to compare the diagnostic performance of the Liver Imaging Reporting and Data System 
(LI-RADS), which incorporates fixed criteria, and the Likert scale (LS), which mainly depends on an overall impres-
sion in liver lesion diagnosis. 
Material and methods: Diagnostic data of 110 hepatic nodules in 103 high-risk patients for hepatocellular carcinoma 
(HCC) were included. Data including diameter, arterial hyperenhancement, washout, and capsule were reviewed by 
2 readers using LI-RADS and LS (range, score 1-5). Inter-reader agreement (IRA), intraclass agreement (ICA), and 
diagnostic performance were determined by Fleiss, Cohen’s k, and logistic regression, respectively.
Results: There were 53 triphasic enhanced computed tomography (CT) and 50 dynamic magnetic resonance (MR) 
examinations. Overall, IRA was excellent (k = 0.898). IRA was good for arterial hyperenhancement (k = 0.705), 
washout (k = 0.763), and capsule (k = 0.771) and excellent for diameter (k = 0.981) and tumour embolus (k = 0.927). 
Overall, ICA between LI-RADS and LS was fair 0.32; ICA was good for scores of 1 (k = 0.682), fair for scores  
of 2 (k = 0.36), moderate for scores of 5 (k = 0.52), but no agreement was found for scores of 3 (k = –0.059) and  
4 (k = –0.022). LIRADS produced relatively high accuracy (87.3% vs. 80%), relatively low sensitivity (84.3% vs. 98%), 
and significantly higher specificity (89.83% vs. 64.4%) and positive likelihood ratio (+LR: 8.29 vs. 2.75) compared 
to LS approach.
Conclusions: LI-RADS revealed higher diagnostic accuracy as compared to LS with statistical proof higher specificity 
and +LR showing its ability to foretell malignancy in high-risk patients. We recommend the practical application of 
the LI-RADS system in the detection and treatment response monitoring of patients with HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most preva-
lent tumours worldwide. The highest incidence rates of 
HCC (around 85% of cases) are present in East Asia, sub-
Saharan Africa, and Melanesia [1]. 
Because proper staging comes from an accurate dia-
gnosis of HCC, many systems have been developed for 
the characterization of different liver lesions, and one 
of these systems is the Liver Imaging Reporting and 
Data System (LI-RADS). It was developed to overcome 
difficulties in the characterization of different liver le-
sions, especially HCC, which was derived from a lack 
of standardization of liver imaging reporting leading to 
wide variability in interpretation and diagnosis of liver 
lesions [2]. 
Classical features of HCC, i.e., arterial enhancement, 
porto-venous washout, and the appearance of the delayed 
capsule, or the so-called criteria-free approach or Likert 
scale (LS), were used to diagnose HCC [3-5].
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The LI-RADS is a reporting system that is designed 
to improve and reduces variability and difficulties in the 
elucidation of imaging findings leading to the most ac-
curate diagnosis, proper staging, and hence, proper treat-
ment [6,7].
Therefore, the purpose of our study was to compare 
the diagnostic performance of LI-RADS and the LS to op-
timize the diagnosis of HCC.
Material and methods
Patients
This retrospective study was approved by the Institutio-
nal Review Board, and informed written consent was ob-
tained for the use of the data of the enrolled individuals.
The study included high-risk patients for HCC (i.e., with 
history of long-term hepatitis or cirrhosis) with the pres-
ence of imaging studies (triphasic computed tomography 
[CT] and dynamic magnetic resonance imaging [MRI]) 
and availability of either diagnosis proven by surgical inter-
ventions or biopsy or the presence of follow-up studies.
Patients who had previous loco-regional treatment 
(transarterial chemoembolization [TACE] or radiofre-
quency [RF] ablation) before the imaging study or pre-
vious surgery/biopsy revealing hepatic malignancy other 
than HCC were excluded from the study. 
According to the Child-Pugh scoring system, of these 
103 patients, 53 were Child-Pugh score A, 39 were Child-
Pugh score B, and 11 were Child-Pugh score C preclud-
ing the possibility of surgical or radiological intervention. 
The performance status (PS) of scores A and B ranged 
from 0 to 2 while the PS of those with score C was above 2.
CT examinations were performed on a 64-row scan-
ner (GE Light Speed). First, non-enhanced scanning was 
performed at a tube voltage of 120 kVp (180 milli-ampere 
seconds, 0.8 pitch, 0.5 s/rotation, DFOV 42 cm2, matrix 512 
× 512, and 32 × 1.2 mm collimation). Patients were then in-
jected with nonionic contrast material (Ultravist 370; Bayer 
Schering Pharma, Berlin, Germany) using a CT-compatible 
power injector. Scans were acquired during the late hepatic 
arterial phase, portal venous phase, and the delayed phase.
MRI examination was performed with a 1.5 T scanner 
(Philips Achieva). First, a pre-contrast study was performed 
followed by a dynamic study performed after a manual 
bolus injection of 0.1 mmol/kg body weight of Gd-DTPA 
and flushed with 20 ml of sterile saline solution. It com-
prised 4 successive post-contrast series including early 
arterial, late arterial, and portal phases with 19-21-second 
intervals (17 s for image acquisition with breath-holding 
and 2-4 s for re-breathing). This was followed by 3-min 
delayed phase imaging. All patients were imaged in end-
expiration to limit the risk of image misregistration. Func-
tional diffusion-weighted imaging (DWI) was performed 
using single-shot spin-echo-planar imaging during one or 
more breath holds.
Image evaluation
Analysis of the CT and MRI studies was accomplished by 
independent double reading by 2 different imaging radio-
logists with at least 10 years’ experience. The readers inde-
pendently reviewed each hepatic focal lesion, the 1st reader 
using LI-RADS and the 2nd reader using the LS. Readers 
were blinded to each other’s analysis.
The first reader, using LI-RADS, evaluated each le-
sion in the liver for 6 imaging features: tumour diameter, 
arterial phase hyper-enhancement, washout appearance, 
capsule, tumour embolus within a vein, and the tumour 
growth rate if possible within 6 months, then the reader 
assigned a final LI-RADS score in the range 1-5.
The second reader used the LS. He measured the largest 
diameter of the liver observation in the axial plane on the 
sequence, where the observation was best depicted, then 
he assessed each lesion for the enhancement pattern, wash-
out appearance, capsule appearance, presence of a tumour 
within a vein, T2 signal as compared to the liver paren-
chyma, and lesion signal on DWIs and apparent diffusion 
coefficient (ADC) map. Finally, he assigned a likelihood 
score for HCC on a 5-point LS, on which LS-1 was defined 
as definitely benign, LS-2 probably benign, LS-3 indetermi-
nate, LS-4 probably HCC, and LS-5 definitely HCC.
Statistical analysis
Data were analysed using IBM SPSS advanced statis-
tics (Statistical Package for Social Sciences), version 22 
(SPSS Inc., Chicago, IL). Qualitative data were described 
as numbers and percentages. McNemar’s test was used to 
examine the relationship between paired nominal data. 
The k statistic was used to assess inter-rater agreement 
between the 2 scales. The 95% confidence intervals, 
sensitivity, specificity, positive value of prediction, and neg-
ative value of prediction with their 95% confidence interval 
were calculated. A p-value less than or equal to 0.05 was 
considered statistically significant. All tests were 2-tailed. 
Results
Sixty-two patients were males (60.25) and 41 were females 
(39.80%). Their mean age was 59.3 ± 12.3 (SD) years. 
A final cohort of a total of 103 examinations was done 
(53 triphasic CT study [51.45%] and 50 dynamic MRI 
study [48.50%]). Of the 103 included patients, a total of 
110 hepatic focal lesions were determined by CT or MR 
imaging. This included 51 HCC lesions and 59 non-HCC 
lesions (Table 1).
First, the inter-reader agreement for major diagnostic 
features of HCC (Table 2) was calculated. It was almost 
perfect for measured diameter (k = 0.981), good for de-
termination of arterial phase enhancement (k = 0.705), 
porto-venous phase washout (k = 0.763), and capsule 
appearance (k = 0.771), and it was excellent for deter-
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mination of tumour embolus within a vein (k = 0.927). 
The overall inter-reader agreement for the final score was 
also excellent (k = 0.898).
The comparison between the frequency of major fea-
tures detected by both the LI-RADS and the LS systems 
revealed similar results. Arterial phase enhancement was 
the most frequently observed major criterion, seen in 
67/110 (60.9%) of lesions using the LR system and seen 
in 66/110 (60.0%) in LS. Washout appearance was the 
second most frequently detected major criterion, seen in 
45/110 (40.9%) of lesions using the LR system and seen 
in 54/110 (49.10%) using the LS. Capsule appearance was 
seen only in 24/110 versus 27/110 (21.8% vs, 24.5%) of 
lesions seen in LR versus LS, respectively. 
The distribution of integrated scores using both systems 
is illustrated in Figure 1, and the percentage of overscoring 
and underscoring of the LS over LI-RADS as well as the 
intraclass agreement of both systems are shown in Table 3.
The total k agreement between the 2 methods for 
stratifying 110 hepatic lesions in this study was 0.32. (fair 
agreement). Both scoring methods show good agreement 
at score 1 (k = 0.682), fair agreement at score 2 (k = 0.36), 
and moderate agreement at score 5 (k = 0.52). There was 
no agreement between the 2 scoring methods at score 3 
(k = –0.059) and score 4 (k = -0.002).
As compared with LI-RADS, the LS approach pro-
duced 36% (9/25) overscoring and 16% (4/25) underscor-
ing of the lesions with LR-3 and resulting in 44.4% (4/9) 
overscoring and 33% (3/9) underscoring of the lesions 
with LR-4.
 The diagnostic performance of each scale for determi-
nation of HCCs is shown in Figure 2. LI-RADS produced 
higher accuracy (87.3% vs. 80%), lower sensitivity (84.3% 
vs. 98%), and significantly higher specificity (89.83% vs. 










 Score 1 Score 2 Score3 Score 4 Score5
LI-RADS scoring system
Likert scale
Table 3. Comparison of the scoring results and the intraclass agreement of Liver Imaging Reporting and Data System (LI-RADS) and Likert scale (LS) approach
 
 
LI-RADS LS Under Over Cohen k 
n % n % n % n %
Score 1 21 19.10 27 24.50 0/21 0 3/21 14.29 0.682 (0.514, 0.85)
Score 2 15 13.60 12 10.90 8/15 53 1/15 6.67 0.368 (0.108, 0.628)
Score 3 25 22.70 13 11.80 4/25 16 9/25 36.00 –0.059 (–0.215, 0.097)
Score 4 9 8.20 29 26.40 3/9 33 4/9 44.44 –0.0220 (–0.166, 0.122)
Score 5 40 36.40 29 26.40 17/40 43 0/40 0.00 0.520 (0.35, 0.69)
Total 110 100.00 110 100.00 32/110 29 17/110 15.45 0.324 (0.21, 0.43)
Table 1. Analysis of non-hepatocellular carcinoma lesions
n %
Adenoma 2 3.40
Atypical haemangioma 4 6.80
Cirrhosis and steatosis 1 1.70
Cysts 5 8.50
Dysplastic nodules 3 5.10
Focal dysplasia 1 1.70
Focal infiltration 3 5.10
Typical haemangioma 20 33.90
Hyperplasia, no malignancy 1 1.70
Hydatid cyst 1 1.70
Inflammation 2 3.40
Regeneration nodules 10 16.90
Siderotic nodules 2 3.40
THIDS 4 6.80
Total 59 100.00
Table 2. Inter-reader agreement for major diagnostic features of hepato-
cellular carcinoma
k coefficient
Arterial enhancement 0.705 (0.831, 0.579)
Porto-venous washout 0.763 (0.885, 0.641)
Capsule 0.771 (0.917, 0.625)
Tumour within a vein 0.927 (1.029, 0.825)
Size (mm) 0.981 (0.972, 0.987)
Final score 0.898 (0.852, 0.93)
[%
]
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64.4%) in correlation to the LS approach. LI-RADS had 
also a higher positive likelihood ratio (+LR: 8.29 vs. 2.75) 
and higher positive predictive value (Ppv = 87.80% vs. 
70.42%) than did the LS approach.
Discussion
In this study, we investigated the diagnostic performance 
of both the LI-RADS system and the LS for the diagnosis 
of HCC. We found that both LI-RADS and LS delivered 
high diagnostic accuracy, being higher in the LI-RADS 
system (87.3% vs. 80%, respectively). 
The LI-RADS produced lower sensitivity as com-
pared to the LS scale (84.3% vs. 98%, respectively). The 
LS approach delivered significantly lower specificity than 
LI-RADS (64.41% vs. 89.83%). Also, LI-RADS had a high-
er positive likelihood ratio (+LR) than did the LS. 
This was very similar to the results revealed in a com-
parable study by Zhang et al. except they revealed lower 
accuracy of LIRADs as compared to the LS scale, which 
may be related to the strict criteria of LI-RADS for the 
definition of each scale to deliver very high specificity for 
HCC at the expense of reducing its accuracy [2]. 
Another study by Esposito et al. revealed the follow-
ing results using the LI-RADS: accuracy = 80%, sensitivity 
= 72%, and specificity = 93%. As for the LS, the results 
were as follows: accuracy = 79%, sensitivity = 73%, and 
specificity = 87% [8]. Although their study delivered high 
accuracy and sensitivity of both LI-RADS and LS (and 
this may be because of the higher accuracy of MRI studies 
over using both CT and MRI as in our study), their results 
were consistent with our current study results regarding 
higher accuracy and specificity and lower sensitivity of 
LI-RADS as compared to the LS.
Studies by Davenport et al. and Wolfgang et al. showed 
a high inter-reader agreement for arterial enhancement 
Figure 2. Performance for determination of hepatocellular carcinoma 








 Sensitivity Specificity + LR – LR + PV – PV Accuracy
Scoring system by LI-RADS score > 3
Scoring system by Likert scale > 2
Figure 3. Triphasic computed tomography in a 63-year-old patient revealed a 34-mm hepatic observation (E) which is hypo-enhancing relative to liver 
parenchyma in the arterial phase (B). It does not appear to be definitely or probably benign and does not exhibit features of non-hepatocellular carcinoma 
(HCC) malignancy or tumour within a vein; also, there is no “capsule” or “washout” in the delayed phase (D). Using the Liver Imaging Reporting and Data 
System (LI-RADS) table, it was categorized LR-3: intermediate probability for HCC. Using the Likert scale, the lesion shows no appreciable contrast enhance-
ment in the arterial phase (B) and is most conspicuous in the delayed phase (D), which could be hypovascular HCC. This lesion was assigned LS-4. Biopsy and 
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Figure 4. Dynamic magnetic resonance imaging depicts multiple hepatic observations, the largest measuring 22 mm in diameter (A). They are showing 
arterial phase peripheral rim of enhancement (A, B). The rim of arterial-phase enhancement progressively expands inwardly in the later phases (C, D) to 
fill most of the observation. The intensity of enhancement approximately parallels that of the blood pool. These observations were thought to be typical 
haemangiomas and considered probably benign. Using the Liver Imaging Reporting and Data System (LI-RADS) table, they were categorized LR-1: defi-
nitely benign. Using the Likert scale, the largest is seen at segment IV measuring 22 mm in diameter (A) eliciting high signal intensity in T2WIs (E) and 
heavy T2 (F) with peripheral nodular enhancement in the arterial phase (A, B) and progressive centripetal filling of contrast in the following phases (C, D), 
probably multiple hepatic haemangiomata. These lesions were assigned LS-1. Biopsy and histopathological results confirmed benign hepatic haemangioma 
(non-hepatocellular carcinoma group)
Figure 5. Dynamic magnetic resonance imaging shows a 41-mm heterogeneous mass (D) that is hypo-enhancing to the liver parenchyma in the arterial 
phase (A). It does not appear to be definitely or probably benign and does not exhibit features of non-hepatocellular carcinoma (HCC) malignancy or tumour 
within a vein. “Capsule” is visible on delayed phase imaging (C). There is no washout appearance in the delayed phase, which could be atypical HCC (C). Using 
the Liver Imaging Reporting and Data System (LI-RADS) table, it was categorized as LR-4: probably HCC. Using the Likert scale, it was assigned LS-4. This 
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and a moderate agreement for washout appearance and 
pseudo-capsule [9,10]. This is comparable to our study re-
sults revealing that the inter-reader agreement was good for 
the determination of arterial phase enhancement, porto- 
venous phase washout, and capsule, indicating some dif-
ficulties in the definition of some specific imaging features 
between the different readers.
This study revealed obvious variations in liver lesions 
reported by the LI-RADS and LS approaches. The lesions 
with definitely benign, probably benign, and malignant 
were well classified by both methods. There were incon-
sistencies, particularly a lack of agreement between the 2 
methods for the classification of intermediate and prob-
able HCC. We noted that the differences mainly appeared 
in the characterization of lesions with score 3 and score 4 
(intermediate and probable HCC), and this was consistent 
with the study by Zhang et al. that also showed obvious 
variations in liver lesions reporting between the LI-RADS 
and LS methods [2]. Both of them were consistent in the 
determination of the lesions with the definitely benign 
and probably benign, moderate agreement in stratifying 
intermediate and definite malignancies, but showed poor 
agreement in the determination of probable malignancy 
and revealed that variations between both scoring systems 
were mostly found in the determination of intermediate 
and probable HCC lesions.
This study had some limitations. First, it was a single-
centre retrospective study, which may have led to some 
bias in the patient selection. Second, we used different im-
aging modalities that might introduce some heterogeneity, 
but it can be also seen as a point of strength because this 
heterogeneity is our everyday clinical practice.
Finally, we used follow-up and histopathology as our 
reference standard, and the imaging follow-up is not as 
pertinent as the histopathology because not all liver le-
sions undergo histopathological correlation giving the fact 
there is a trend towards replacing pathology with accurate 
diagnostic imaging.
Conclusions
Hepatocellular carcinoma can be diagnosed and properly 
staged using different imaging modalities aimed at achiev-
ing high specificity. The LI-RADS and LS systems repre-
sent basic approaches for the diagnosis of HCC. Many 
differences were found in liver lesions reporting by the 
LI-RADS and LS methods. In our work, the LI-RADS re-
vealed higher diagnostic accuracy as compared to LS, with 
statistical proof of higher specificity and positive likeli-
hood ratio indicating its ability to foretell malignancy in 
the high-risk patients. We recommend the practical appli-
cation of the LI-RADS system in the detection and treat-
ment response monitoring of patients with HCC.
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Figure 6. Triphasic computed tomography revealed a 50 mm hepatic observation (C) which is hypo-enhancing relative to liver parenchyma in the arterial 
phase (B). It does not appear to be definitely or probably benign and does not exhibit features of non-hepatocellular carcinoma (HCC) malignancy or tumour 
within a vein; also, there is no “capsule” or “washout” in the delayed phase (D). Using the Liver Imaging Reporting and Data System (LI-RADS) table, it was 
categorized LR-3: intermediate probability for HCC. Using the Likert scale, the possibility of hypovascular/atypical HCC could not be excluded, so it was 
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